

8. References:

- Abate G., T. Kiovula and S.E. Hoffner. 2002. In vitro activity of thiacetazone on mycobacterial species belonging to the *Mycobacterium tuberculosis* complex, The International Journal of Tuberculosis and Lung disease. **6**: 933-935
- Abdel-Salam M.S. and W. Klingmuller. 1987. Transposon Tn5 mutagenesis in *Azospirillum lipoferum*: isolation of indole acetic acid mutants, Molecular Genetics. **210**: 165-170
- Abrahams T.J. 2004. Antibacterial marine bacterium deter luminous vibrosis in shrimp larvae, NAGA Worldfish Quarterly. **27**: 28-31
- Adam M., B. Murali, N.O. Glenn and S.S. Potter. 2008. Epigenetic inheritance based evolution of antibiotic resistance in bacteria, Biomed Central Evolutionary Biology. **8**: 52
- Alahari A., X. Trivelli, Y. Guérardel, L.G. Dover, G.S. Besra, J.C. Sacchettini, R.C. Reynolds, G.D. Coxon and L. Kremer. 2007. Thiacetazone, an antitubercular drug that inhibits cyclopropination of cell wall mycolic acids in Mycobacteria, Plus One. **2**: e1343
- Andries K., P. Verhasselt, J. Guillemont, H.W.H. Göhlmann, J. Neefs, H. Winkler, J. Van Gestel, P. Timmerman, M. Zhu, E. Lee, P. Williams, D. de Chaffoy, E. Huitric, S. Hoffner, E. Cambau, C. Truffot-Pernot, N. Lounis and V. Jarlier. 2005. A diarylquinoline drug active on the ATP synthase of *Mycobacterium tuberculosis*, Science. **307**: 223-227
- Ameran.C., C. Paillard, F. Robin, J. Kanold, O. Baud, R. Bonnet, B. Souweine, O. Traore. 2007. *Pseudomonas aeruginosa* and *Pseudomonas putida* outbreak associated with contaminated water outlets in an oncohaematology paediatric unit. Journal of Hospital Infection. **65**: 47-53

Anderson D.M. and D. Mills. 1985. The use of transposon mutagenesis in the isolation of nutritional and virulence mutants in two pathovars of *Pseudomonas syringae*, *Phytopathology*. **75**: 104-108

Arevalo-Ferro C., G. Reil , A. Görg, L. Eberl and K. Riedel. 2005. Biofilm formation of *Pseudomonas putida* IsoF: the role of quorum sensing as assessed by proteomics, *Systematic and Applied Microbiology*. **28**: 87-114

Barbeyron. T., K. Kean and P. Forterre. 1984. DNA adenine methylation of GATC sequences appeared recently in *Escherichia coli* lineage, *Journal of Bacteriology*. **160**: 586-590.

Bakker-Woudenberg I.A.J.M., W. van Vianen, D. van Soolingen, H.A. Verbrugh M.A. van Agtmael. 2005. Antimycobacterial agents differ with respect to their bacteriostatic versus bactericidal activities in relation to time of exposure, mycobacterial growth phase and their use in combination, *Antimicrobial and Chemotherapy*. **49**: 2387-2398

Balganesh T.S., V. Balasubramanian and S.A. Kumar. 2004. Drug discovery for tuberculosis: bottlenecks and path forward, *Current Science*. **86**: 167-175

Banerjee S.K., K. Bhatt and S. Rana. 1996. Involvement of an efflux system in mediating high level of fluoroquinolone-resistance in *Mycobacterium smegmatis*, *Biochemical and Biophysical Research Communications*. **226**: 326-368

Bartos M., J.O. Falkinham and I. Pavlik. 2004. Mycobacterial catalases, peroxidases and superoxide dismutases and their effects on virulence and isoniazid- susceptibility in mycobacteria, *Veterinary Medicine Czech*. **49**: 161-170

Bender C.L., F. Alarcon-Chaidez and D.C. Gross. 1999. *Pseudomonas syringae* phytotoxins: mode of action, regulation, and biosynthesis by peptide and polyketide synthases. *Microbiology and Molecular Biology Reviews*. **63**: 266-292

Bie X., Z. Lu, F. Lu and X. Zeng. 2005. Screening the main factors affecting extraction of the antimicrobial substance from *Bacillus subtilis* fmbJ using plackett-burman method, *World Journal of Microbiology and Biotechnology*. **21**: 925-928

Boyer R. 2006. *Biochemistry laboratory: modern theory and techniques*. Ed: J. Smith, Benjamin Cummings Inc. San Francisco.

Brodhagen M., M.D. Henkels and J.E. Loper. 2003. Positive autoregulation and signalling properties of pyoluteorin, and antibiotic produced by *Pseudomonas fluorescens* Pf5, *Applied and Environmental Microbiology*. **70**: 1758-1766

Buber E., A. Stindl, N.L. Acan, T. Kocagoz, R. Zocher. 2002. Antimycobacterial activity of lipodepsipeptides produced by *Pseudomonas syringae* pv *syringae* B359, *Natural Product Letters*. **16**: 419-423

Buell C. R., V. Joardar, M. Lindeberg, J. Selengut, I.T. Paulsen, M.L. Gwinn, R.J. Dodson, R.T. Deboy, A.S. Durkin, J.F. Kolonay, R. Madupu, S. Daugherty, L. Brinkac, M.J. Beanan, D.H. Haft, W.C. Nelson, T. Davidsen, N. Zafar, L. Zhou, J. Liu, Q. Yuan, H. Khouri, N. Fedorova, B. Tran, D. Russell, K. Berry, T. Utterback, S. E. Van Aken, T.V. Feldblyum, M. D'Ascenzo, W. Deng, A.R. Ramos, J.R. Alfano, S. Cartinhour, A.K. Chatterjee, T.P. Delaney, S.G. Lazarowitz, G.B. Martin, D.J. Schneider, X. Tang, C.L. Bender, O. White, C.M. Fraser and A. Collmer. 2003. The complete genome sequence of the *Arabidopsis* and tomato pathogen *Pseudomonas syringae* pv *tomato* DC300, *Proceedings of the National Academy of Science USA*. **100**: 10181- 10186

Butler M.S. and A.D. Buss. 2006. Natural products – the future scaffolds for novel antibiotics?, *Biochemical Pharmacology*. **71**: 919-929

Carla C.C.R., A.A.R.L. Da Cruz, M. Pons, H.M.R.V. Pinheiro, J.M.S. Cabral, M.M. R. Da Fonseca, B.S. Ferreira, P. Fernandes. 2004. *Mycobacterium* sp. *Rhodococcus erythropolis* and *Pseudomonas putida* behaviour in the presence of organic solvents, *Microscopy Research and Technique*. **64**: 215-222

Caws M., P.M. Duy, D.Q. Tho, N.T.N. Lan, D.V. Hoa and J. Farrar. 2006. Mutations prevalent among rifampin and isoniazid-resistant *Mycobacterium tuberculosis* isolates from a hospital in Vietnam, *Journal of Clinical Microbiology*. **44**: 2333-2337

Chang W. and L.J. Halverson. 2003. Reduced water availability influences the dynamics, development, and ultrastructural properties of *Pseudomonas putida* biofilms, *Journal of Bacteriology*. **185**: 6199-6204

Chatterjee D. 1997. The mycobacterial cell wall: structure, synthesis and sites of drug action. *Current Opinion in Current Biology*. **1**: 579-588

Clardy J., M.A. Fischbach and C.T. Walsh. 2006. New antibiotics from bacterial natural products, *Nature Biotechnology*. **24**: 1541-1550

Co D.O., L.H. Hogan, S.I. Kim and M. Sandor. 2004. Mycobacterial granulomas: keys to a long lasting host-pathogen relationship, *Clinical Immunology*. **113**: 130-136

Cole S.T. and P.M. Alzari. 2005. TB-A new target, a new drug, *Science*. **307**: 214:215

Cupples D.A. 1986. Generation and characterization of Tn5 insertion mutations in *Pseudomonas syringae* pv. tomato. *Applied and Environmental Microbiology*. **51**: 323-327

Daniel M. 2006. The history of tuberculosis. *Respiratory Medicine*. **100**: 1862-1870

Das B.K., S.K. Samal, B.R. Samantaray, S. Sethi, P. Pattnaik and B.K. Mishra. 2006. Antagonistic activity of cellular components of *Pseudomonas* species against *Aeromonas hydrophila*, *Aquaculture*. **253**: 17-24

Davis J.M. and L. Ramakrish. 2008. The very pulse of the machine: the tuberculosis granuloma in motion. *Immunity*. **28**: 146-148

Day D.L., D. Yasinow, J. McDonough, and C.W. Shuster. 1984. Use of ureidopenicillins for selection of plasmid vector transformants in *Pseudomonas aeruginosa* and *Pseudomonas putida*, *Journal of Bacteriology*. **157**: 937-939

De Bruijn I.M., J.D. de Kock, P. de Waard, T.A. van Beek and J.M. Raaijmakers. 2008. Massetolide a biosynthesis in *Pseudomonas fluorescens*, *Journal of Bacteriology*. **190**: 2777-2789

Denamur E. and I. Matic. 2006. Micro review: Evolution of mutation rates in bacteria, *Molecular Microbiology*. **60**: 820-827

Dormann S.E. and, R.E. Chaisson. 2007. From magic bullets back to the magic mountain: the rise of extensively drug-resistant tuberculosis, *Nature Medicine*. **13**: 295-298

Drake J.W., B. Charlesworth, D. Charlesworth and J.F. Crow. 1998. Rates of spontaneous mutation, *Genetics*. **148**: 1667-1686

Drider D., G. Fimland, Y. Héchard, L.M. McMullen and H. Prévost. 2006. The continuing story of class IIa bacteriocins. *Microbiology and Molecular Biology Reviews*. **70**: 564-582

Dubern J.F., E.L. Lagendijk, B.J.J. Lugtenberg and, G.V. Bloemberg. 2005. The heat shock genes *dnaK*, *dnaJ* and *grpE* are involved in regulation of putisolvin biosynthesis in *Pseudomonas putida* PCL1445, *Journal of Bacteriology*. **187**: 5967-5976

Du Toit E.A. and M. Rautenbach. 2000. A sensitive standardised microgel well diffusion assay for the determination of the antimicrobial activity, *Journal of Microbiological Methods*. **42**: 159-165

Egen J.G., A.G. Rothfuchs, C.G. Feng, N. Winter, A. Sher and R.N. Germain. 2008. Macrophage and T cell dynamics during the development and disintegration of mycobacterial granulomas. *Immunity*. **28**: 271-284

Falzari K., Z. Zhu, D. Pan, H. Liu, P. Hongmanee and S.G. Franzblau. 2005. In vitro and in vivo activities of macrolide derivatives against *Mycobacterium tuberculosis*, Antimicrobial Agents and Chemotherapy. **49**: 1447-1454

Fedenuik R.W. and P.J. Shand. 1998. Theory and methodology of antibiotic extraction from biomatrices, Journal of Chromatography A. **812**: 3-15

Fenn J.B. 2002. Electrospray ionisation mass spectrometry: how it all began, Journal of Biomolecular Techniques. **13**: 101–118

Friedman M. 2004. Application of the ninhydrin reaction for analysis of amino acids, peptides and proteins to agricultural and biomedical sciences, Journal of Agricultural and Food Chemistry. **52**: 385-406

Fitzmaurice A.M. and, P.E. Kolattukudy. 1998. An acyl-coA synthase (*acs*) gene adjacent to the mycocerosic acid synthase (*mas*) locus is necessary for mycocerosyl lipid synthesis in *Mycobacterium tuberculosis* var. *bovis* BCG, Journal of Biological Chemistry. **273**: 8033-8039

Fuhr U., G. Strobl, F. Manaut, E.M. Anders, F. Sorgel, E. Lopez-de-Brinas, D.T. Chu, A.G. Pernet, G. Mahr and F. Sanz. 1992. Quinolone antibacterial agents: relationship between structure and in vitro inhibition of the human cytochrome P450 isoform CYP1A2, Molecular Pharmacology. **43**: 191-199

Goryshin I.Y., J. Jendrisack, L.M Hoffman, R. Meis and W.S. Reznikoff. 2000. Insertional transposon mutagenesis by electroporation of released Tn5 transposition complexes. Nature Biotechnology. **18**: 97-100

Grgurina I., M. Bensaci, G. Pocsfalvi, L. Mannina, O. Cruciani, A. Fiore, V. Fogliano, K.N. Sorensen and J.Y. Takemoto. 2005. Novel cyclic lipodepsipeptide from *Pseudomonas syringae* pv. *lachrymans* strain 508 and syringopeptin antimicrobial activities, Antimicrobial Agents and Chemotherapy. **49**: 5037-5045

Gross F. , N. Luniak, O. Perlova, N. Gaitatzis, H. Jenke-Kodama, K. Gerth, D. Gottschalk, E. Dittmann and R. Muller. 2006. Bacterial type III polyketide synthases: phylogenetic analysis and potential for the production of novel secondary metabolites by heterologous expression in pseudomonads, *Archive of Microbiology*. **185**: 28-38

Guven K. 2000. Bacteriocin typing of some Turkish isolates of *Pseudomonas syringae* pv. *phaseolicola*, *Turkish Journal of Biology*. **24**: 795–801

Hamer L., T.M. DeZwaan, M.V. Montenegro-Chamorro, S.A. Frank and J.E Hamer. 2001. Recent advances in large-scale transposon mutagenesis, *Current Opinion in Chemical Biology*. **5**: 67–73

Harries A.D. 1997. Tuberculosis in Africa, *Pharmacological Therapy*. **73**: 1-509

Han N.S. and J.F. Robyt. 1998. Separation and detection of sugars and alditols on thin layer chromatograms, *Carbohydrate Research*. **313**: 135-137

Hayes F. 2003. Transposon based strategies for microbial functional genomics and proteomics, *Annual Review of Genetics*. **37**: 3-29

Helinski D.R. 2004. Chapter 1: Introduction to plasmids: a selective view of their history. *Plasmid Biology*. B.E. Funnell and G.J Phillips (Eds), ASM Press. Washington D.C

Hoffmann A., U. Pag, I. Wiedemann and H. Sahl. 2001. Combination of antibiotic mechanisms in lantibiotics, *Il Farmaco*. **57**: 685-691

Holtmark I., V.G.H. Eijsink and M.B. Brurberg. 2008. Bacteriocins from plant pathogenic bacteria, *Federation of European Microbiological Societies*. **280**: 1–7

Isken S. and J.A.M de Bont. 1998. Bacteria tolerant to organic solvents, *Extremophiles*. **2**: 229-238

Iwalokun B.A., K.A. Akinsinde, O. Lanlenhin and C.C. Onubogu. 2006. Bacteriogenicity and production of pyocins from *Pseudomonas* species isolated in Lagos, Nigeria, *African Journal of Biotechnology*. 5: 1072-1077

Joarder V., M. Lindeberg, R.W. Jackson, J. Selengut, R. Dodson, L.M. Brinkac, S.C. Daugherty, R. DeBoy, A.S. Durkin, M. Gwinn Giglio, R. Madupu, W.C. Nelson, M. J. Rosovitz, S. Sullivan, J. Crabtree, T. Creasy, T. Davidsen, D.H. Haft, N. Zafar, L. Zhou, R. Halpin, T. Holley, H. Khouri, T. Feldblyum, O. White, C.M. Fraser, A.K. Chatterjee, S. Cartinhour, D.J. Schneider, J. Mansfield, A. Collmer and C.R. Buell. 2005. Whole – genome sequence analysis of *Pseudomonas syringae* pv phaseolicola 1448A reveals divergence among pathovars in genes involved in virulence and transposition, *Journal of Bacteriology*, **187**: 6488-6498

Juhas M., L. Eberl and B. Tummler. 2005. Quorum sensing: the power of cooperation in the world of *Pseudomonas*, *Environmental Microbiology*, **7**: 459-471

Korzybski T., Z. Kowszyk-Gindifer and W. Kurylowicz. 1967. Antibiotics: origin, nature and properties I, Pergamon Press. Oxford.

Korzybski T., Z. Kowszyk- Gindifer and W. Kurylowicz. 1976. Antibiotics: origin, nature and properties II, Pergamon Press. Oxford.

Kruger R.S., A. Rakowski and M. Filutowicz. 2004. Chapter 2: Participating elements in the replication of iteron-containing plasmids. *Plasmid Biology*. B.E. Funnell and G.J Phillips (Eds). ASM Press. Washington D.C

Kuiper I., E.L. Lagendijk, R. Pickford, J.P Derrick, G.E. Lamers and J.E Thomas-Oates. 2004. Characterization of two *Pseudomonas putida* lipopeptide biosurfactants, putisolvin I and II, which inhibit biofilm formation and breakdown existing biofilms, *Molecular Microbiology*. **51**: 97-113

Lodge J.K., K. Weston-hafer and D.E. Berg. 1988. Transposon Tn5 sepcificity: preference for insertion at G/C pairs, *Genetics*. **120**: 645-650

Louie T.J., F.P. Tally, J.G. Bartlett, S.L. Gorbach. 1976. Rapid microbiological assay for chlorophenicol and tetracyclines, *Antimicrobial Agents and Chemotherapy*. **9**: 874-878

MacDonnell G. and A.D. Russell. 1999, Antiseptics and disinfectants: activity, action, and resistance, *Clinical Microbiological Reviews*. **12**: 147-179

Mahrotra J. and W.R. Bashai. 2001. Regulation of virulence genes in *Mycobacterium tuberculosis*, *International Journal of Medical Microbiology*. **291**: 171-182

Makovitzki A., D. Avrahami and Y. Shai. 2006. Ultrashort antibacterial and antifungal lipopeptides, *Proceedings of the National Academy of Sciences USA*. **103**: 15997-16002

Mangold H.K. 1961. Thin layer chromatography of lipids, *The Journal of the American Oil Chemists Society*. **38**: 708-727

Maus C.E., B.B. Plikaytis and T.M. Shinnick. 2005. Molecular analysis of cross resistance to capreomycin, kanamycin, amikacin and viomycin in *Mycobacterium tuberculosis*, *Antimicrobial Agents and Chemotherapy*. **49**: 3192-3197

McClellan K.H., M.K. Winson, L. Fish, A. Taylor, S.R. Chabra, R. Camara, M. Daykin, J.H. Lamb, S. Swift, B.W. Bycroft, G.B. Stewart and P. Williams. 1997. Quorum sensing and *Chromobacterium violaceum*: exploitation of violacein production and inhibition for the detection of *N*-acylhomoserine lactones, *Microbiology*. **143**: 3703-3711

Mdluli K. and M. Spigelman. 2006. Novel targets for tuberculosis drug discovery, *Current Opinion in Pharmacology*. **6**: 459-467

Milcamps A., D.M. Ragatz, P. Lim, K.A. Berger and F.J. de Bruijn. 1998. Isolation of carbon- and nitrogen deprivation induced- loci *Sinorhizobium meliloti* 1021 by Tn5-luxAB mutagenesis, *Microbiology*. **144**: 3205-3218

Moll G., H. Hildeng-Hauge, I.F. Nes, W.N. Konings and A.J.M Driessen. 1998. Mechanistic properties of the two-component bacteriocin lactococcin G, Journal of Bacteriology. **180**: 96-99

Moll G., T. Ubbink-kok, H. Hildeng-Hauge, J. Nissen-Meyer, I.F. Nes, W.N. Konings and A.J.M Driessen. 1996. Lactococcin G is a potassium ion-conducting, two-component bacteriocins, Journal of Bacteriology. **178**: 600-605

Morris R.P., L. Nguyen, J. Gatfield, K. Viscont, K. Ngyuen, D. Schnappinger, S. Ehrt, Y. Liu, L. Heifets, J. Pieters, G. Schoolnik and C.J. Thompson. 2005. Ancestral antibiotic resistance in *Mycobacterium tuberculosis*, Proceedings of the National Academy of Sciences USA. **102**: 12200-12205

Muller R. and H.B. Bode. 2005. The impact of bacterial genomics on natural product research, Angewandte Chemie International Edition. **44**: 6828-6846

Murinda S.E., R.F. Roberts and R.A. Wilson. 1996, Evaluation of colicins for inhibitory activity against diarrheagenic *Escherichia coli* strains, including serotype O157:H7, Applied and Environmental Microbiology. **62**:3196-3202

Muto A. and S. Osawa. 1987. The guanine and cytosine content of genomic DNA and bacterial evolution, Proceedings of the National Academy of Science USA. **84**: 166-169

Nathan C. 2004. Antibiotics at the crossroads, Nature. **431**:899-902

Nelson K.E. 2002. Complete genome sequence and comparative analysis of the metabolically versatile *Pseudomonas putida* KT2440, Environmental Microbiology. **4**: 799-808

Newman D.J. and G.M. Cragg. 2007. Natural products as sources of new drugs over the last 25 years, Journal of Natural Products. **70**: 461- 477.

Nielsen T.H., D. Sørensen, C. Tobiasen, J.B. Andersen, C. Christophersen, M. Givskov and J. Sørensen. 2002. Antibiotic and biosurfactant properties of cyclic lipopeptides produced by fluorescent *Pseudomonas spp* from the sugar beet, *Applied and Environmental Microbiology*. **68**:3416-3423

Norrby S.R., C.E. Nord, and R. Finch. 2005. Lack of development of new antimicrobial drugs: a potential serious threat to public health, *Lancet Infectious Diseases*. **5**:115-119

Ochi K. 1995. Comparative ribosomal protein sequence analyses of a phylogenetically defined genus, *Pseudomonas* and its relatives, *International Journal of Systematic Bacteriology*. **45**:268-273

Omura S. 1986. Philosophy of new drug discovery, *Microbiological Reviews*. **50**: 259-279

Paramasivan C.N., S. Sulochana, G. Kubendiran, P. Venkatesan and D. A. Mitchison. 2005. Bactericidal action of gatifloxacin, rifampin and isoniazid on logarithmic and stationary phase cultures of *Mycobacterium tuberculosis*, *Antimicrobial Agents and Chemotherapy*. **49**:627-631

Parret A.H.A. and R. De Mot. 2002. Bacteria killing their own kind: novel bacteriocins of *Pseudomonas* and other γ -proteobacteria, *Trends in Microbiology*. **10**: 107-112

Paulsen I.T., C.M. Press, J. Ravel, D.Y. Kobayashi, G.S.A. Myers, D.V. Mavrodi, R.T. DeBoy, R. Seshadri, Q. Ren, R. Madupu, R.J. Dodson, A.S. Durkin, L.M. Brinkac, S.C. Daugherty, S.A. Sullivan, M.J. Rosovitz, M.L. Gwinn, L. Zhou, D.J. Schneider, S.W. Cartinhour, W.C. Nelson, J. Weidman, K. Watkins, K. Tran, H. Khouri, E.A. Pierson, L.S. Pierson III, L.S. Thomashow and J.E. Loper. 2006. Complete genome sequence of the plant commensal *Pseudomonas fluorescens* Pf-5, *Nature Biotechnology*. **23**: 873-878

Payne D.J., M.N. Gwynn, D.J. Holmes and D.L. Pompliano. 2007. Drugs for bad bugs: confronting the challenges of antibacterial discovery, *Nature Reviews*. **6**: 29-40

Pillai S.D. and I.L. Pepper. 1991. Transposon Tn5 as an identifiable marker in *Rhizobia*: survival and genetic stability of Tn5 mutant bean *Rhizobia* under temperature stressed conditions in desert soils, *Microbial Ecology*. **21**:21-33

Poole C.F. and S.K. Poole. 1989. Modern thin layer chromatography, *Analytical Chemistry*. **61**: 1257a-1269a

Potterat O. and M. Hamburger. 2006. Natural products in drug discovery - concepts and approaches for tracking bioactivity, *Current Organic Chemistry*. **10**: 899-920

Qian L. and P.R.O. de Montellano 2006. Oxidative action of thiacetazone by the *Mycobacterium tuberculosis* flavin monooxygenase Eta and human FMO1 and FMO3, *Chemical Research in Toxicology*. **19**: 443- 449

Raaijmakers J.M., I. Bruijn and, M.J.D. de Kock. 2006. Cyclic lipopeptide production by plant-associated *Pseudomonas* spp: diversity, activity, biosynthesis and regulation, *Molecular Plant-Microbe Interactions*. **19**: 699-710

Ramaswamy V.S., R. Reich, S. Dou, L. Jasperse, X. Pan, A. Wanger, T. Quitugua,³ and E.A. Graviss. 2003. Single nucleotide polymorphisms in genes associated with isoniazid resistance in *Mycobacterium tuberculosis*, *Antimicrobial Agents and Chemotherapy*. **47**: 1241-1250

Rautenbach M., G.D. Gerstner, N.M. Vlok, J. Kulenkampff and H.V. Westerhoff. 2006. Analyses of dose-response curves to compare the antimicrobial activity of model cationic α helical peptides highlights the necessity for a minimum of two activity parameter, *Analytical Biochemistry*. **350**: 81-90

Rios J.L., M.C. Recio. and A. Villar. 1988. Screening methods for natural products with antimicrobial activity: a review of literature, *Journal of Ethnopharmacology*. **23**: 127-149

Reznikoff W.S. 1993. The Tn5 transposon, Annual Reviews in Microbiology. **47**: 945- 963

Reznikoff W.S. 2003. Tn5 as a model for understanding transposition, Molecular Microbiology. **47**: 1199-1206

Sambrook J., E.F. Frisch and T. Maniatis. 1989. Molecular Cloning: A laboratory manual, Cold Spring Harbour Laboratory press. New York.

Sandy J., S. Holton, E. Fullam, E. Sim and M. Noble. 2007. Binding of the anti-tubercular drug isoniazid to the arylamine N-acetyltransferase protein from *Mycobacterium smegmatis*, Protein Science. **14**: 755-782

Santa Anna L.M., G.V. Sebastian, N. Pereira Jr., T.L.M. Alves, E.P. Menezes and D.M.G. Freire. 2001. Production of biosurfactant from a new promising strain *Pseudomonas aeruginosa* PA1, Applied Biochemistry and Biotechnology. **91**: 459-467

Saunders B.M. and W.J. Britton. 2007. Life and death in the granuloma: immunopathology of tuberculosis. Immunology and Cell Biology. **85**: 103-111

Schmitz S., A. Hoffmann, C. Szekat, B. Rudd, G. Bierbaum. 2006. The lantibiotic mesacidin is an autoinducing peptide, Applied and Environmental Microbiology. **72**: 7270-7277

Schnider U., C. Keel, C. Voisard, G. Défago and D. Haas. 1995. Tn5- directed cloning of *pqq* genes from *Pseudomonas fluorescens* CHA0: mutational inactivation of the gene results in overproduction of the antibiotic pyoluteorin, Applied and Environmental Microbiology. **61**: 3856-3864

Shah D.S., M.A. Cross, D. Porter and C.M. Thomas. 1995. Dissection of the core of vegetative replication origin of promiscuous plasmid RK2, Journal of Molecular Biology. **254**: 608-622

Silva M., N.V. Jacobus, C. Deneke and S.L. Gorbach. 1987. Antimicrobial substance from a human *Lactobacillus* strain, *Antimicrobial Agents and Chemotherapy*. **31**: 1231-1233

Singh J.A., R. Upshur and N. Padayatchi. 2007. XDR-TB in South Africa: no time for denial or complacency, *PLoS medicine*.**4**: 0019-0025

Siuzdak G. 1994. Review: The emergence of mass spectrometry in biochemical research, *Proceedings of the National Academy of Sciences USA*. **91**: 11290-11297

Spiers A.J., A. Buckling and P.B. Rainey. 2000. The causes of *Pseudomonas* diversity, *Microbiology*. **146**: 2345–2350

Sorenson K.N., K. Kim and J.Y. Takemoto. 1996. In vitro antifungal and fungicidal activities and erythrocyte toxicities of cyclic lipodepsinona peptides produced by *Pseudomonas syringae* pv *syringae*, *Antimicrobial Agents and Chemotherapy*. **40**: 2710-2713

Sriram D., A. Aubry, P. Yogeeswari and L.M. Fisher. 2006. Gatifloxacin derivatives: synthesis, antimycobacterial activities, and inhibition of *Mycobacterium tuberculosis* DNA gyrase, *Bioorganic and Medicinal Chemistry Letters*. **16**: 2982-2985

Stauton J. and K.J. Weissman. 2001. Polyketide biosynthesis: a millennium review, *Natural Product Report*. **18**: 380-416

Stover C.K., X.Q. Pham, A.L. Erwin, S.D. Mizoguchi, P. Warrener, M.J Hickey, F.S. Brinkman, W.O. Hufnagle, D.J. Kowalik, M. Lagrou, R.L. Garber, L. Goltry, E. Tolentino, S. Westbrook-Wadman, Y. Yuan, L.L. Brody, S.N. Coulter, K.R. Folger, A. Kas, K. Larbig, R. Lim, K. Smith, D. Spencer, G.K. Wong, Z. Wu, I.T. Paulsen, J. Reizer, M.H. Saier, R.E. Hancock, S. Lory and M.V. Olson. 2000, Complete genome sequence of *Pseudomonas aeruginosa* PAO1 an opportunistic pathogen, *Nature*. **406**: 959- 964

Strauss S.K. and R.E.W. Hancock. 2006. Mode of action for the new antibiotic for gram positive pathogens daptomycin: comparison of cationic antimicrobial peptides and lipopeptides, *Biochemica and Biophysica Acta*. **1758**: 1215-1223

Tegova R., A. Tover, K. Tarassova, M. Tark and M. Kivisaar. 2004. Involvement of error prone DNA polymerase IV in stationary phase mutagenesis in *Pseudomonas putida*, *Journal of Bacteriology*. **186**: 2735-2744

Tingyue G. 2000. Handbook of bioseparations Volume 2. Chapter 7: Liquid –liquid partitioning methods for bioseparations, Ed: S. Ahuja, Academic Press

Van den Broek D., T.F.C. Chin-a-woeng, K. Eijkemans, I.H.M. Mulders, G.V. Bloemberg and B.J.J. Lugtenberg. 2003. Biocontrol traits of *Pseudomonas* spp. Are regulated by phase variation, *Molecular Plant Microbe Interaction*. **16**: 1003-1012

Vangapandu S., M. Jain, S. Kaur and P.P. Singh. 2004. Ring-substituted quinolones as potential anti-tuberculosis agents, *Bioorganic and Medicinal Chemistry*. **12**: 2501-2508

Vilcheze C. and W.R. Jacobs.Jr. 2007. The mechanism of isoniazid killing: clarity through the scope of genes, *Annual Review Microbiology*. **61**: 35-50

Vlachos V., A.T. Critchley and A. von Holy. 1996. Establishment of a protocol for testing antimicrobial activity in southern African macroalgae, *Microbios*. **88**: 115-123

Vlachos V., A.T. Critchley and A. von Holy. 1997. Antimicrobial activity of extracts from selected southern African marine algae, *South African Journal of Science*. **93**: 328-332

Walsh C.T. 2007. Chemical versatility of natural product assembly lines, *Accounts of Chemical Research*. **30**: 40

Walsh C.T. 2000. Molecular mechanisms that confer antibacterial drug resistance. *Nature*. **406**: 775-781

Wawrik, B., L. Kerkhof, G.J. Zylstra and J.J. Kukor. 2005. Identification of type II polyketide synthase genes in soil, *Applied and Environmental Microbiology*. **71**: 2232-2238

Wolk P., Y. Cai and J. Panoff. 1991. Use of transposon with luciferase as a reporter to identify environmentally responsive genes in a *Cyanobacterium*, *Proceedings of the National Academy of Science USA*. **88**: 5355-5359

Wratten S.J., M.S. Wolfe, R.J. Andersen and D.J. Faulkner. 1977. Antibiotic metabolites from a marine pseudomonad, *Antimicrobial Agents and Chemotherapy*. **11**: 411- 414

Yang L.H., L. Xu, L. He, J. Terracciano, M. Patel, V. Gullo, T. Black, W. Zhao, T. Chan and M. Chu. 2007. Effect of agitation on violacein production in *Pseudomonas luteoviolacea* isolated from a marine sponge, *Letters in Applied Microbiology*. **44**: 625-630

Yang S.W., L. Xu, R. Mierzwa, L. He, J. Terracciano, M. Patel, V. Gullo, T. Black, W. Zhao, T. Chan and M. Chu. 2004. Two novel antibiotics, Sch 419558 and Sch 419559, produced by *Pseudomonas fluorescens*: effect on activity by overexpression of RpoE, *Bioorganic Medicinal Chemistry*. **12**: 3333-3338

Yan L.M., K.G. Boyd and J.G. Burgess. 2002. Surface attachment induce production of antimicrobial compounds by marine epiphytic bacteria using modified roller bottle cultivation, *Marine Biotechnology*. **4**: 356-366

Yarbrough G.G., D.P. Taylor, R.T. Rowlands, M.S. Crawford and L.L. Lasure. 1993. Screening microbial metabolites for new drugs- theoretical and practical issues, *The Journal of Antibiotics*. **46**: 535-544

Yee T.W. and D.W. Smith. 1990. *Pseudomonas* chromosomal replication origins: a bacterial class distinct from *Escherichia coli*-type origins, *Proceedings of the National Academy of Science USA*. **87**: 1278-1282

Yem E.W. and E.C. Cocking. 1955. The determination of amino acids with ninhydrin and iridium by iron exchange, Chemistry Department University of Bristol Publication. **80**: 209-214

Zhang Y. 2005. The magic bullets and tuberculosis drug targets, Annual Review of Pharmacology and Toxicology. **45**: 529-564

Zhang Z. and L.S. Pierson.III. 2001. A second quorum sensing system regulates cell surface properties but not phenazine antibiotic production on *Pseudomonas aureofaciens*, Applied Environmental Microbiology. **67**: 4305-4315

Zu Bentrap K.H. and D.G. Russell. 2001. Mycobacterial persistence: adaptation to a changing environment, Trends in Microbiology. **9**: 597-605

<http://www.nap.edu/catalog/11471.html>, Treating infectious diseases in a microbial world: report of two workshops, National Academic Press, Washington D.C, Committee on the new direction in the study of antimicrobial therapeutics.